title: [Long-term captopril therapy in asymptomatic patients with severe chronic aortic insufficiency].
abstract: BACKGROUND
  Clinical history of patients with severe chronic aortic regurgitation is characterized by a long period without any symptom, although the left ventricle enlarges progressively. The administration of oral vasodilators could reduce ventricular enlargement or its progression, delaying the development of myocardial dysfunction and/or the need for valvular surgery.
  
  
  OBJECTIVE
  To verify the efficacy of long-term captopril therapy to reduce left ventricular mass and dimensions in patients with severe chronic aortic regurgitation.
  
  
  METHODS
  This is a prospective echocardiographic study in which each individual patient is considered his own control case. Eleven asymptomatic patients with severe chronic aortic regurgitation in sinus rhythm, who had an ejection fraction greater than 50% and were not taking cardiovascular drugs, were orally administered captopril at the maximum tolerated dosage (127 +/- 13 mg/day). Follow-up lasted for 24 +/- 3 months.
  
  
  RESULTS
  Left ventricular telediastolic diameter decreased from 69 +/- 5 to 61 +/- 3 mm (p < 0.01), telesystolic diameter decreased from 48 +/- 5 to 41 +/- 4 mm (p < 0.01); ejection fraction increased from 56 +/- 4 to 61 +/- 3% (p < 0.001); myocardial mass decreased from 208 +/- 32 to 174 +/- 27 g/m2 (p < 0.01), and mean wall stress from 264 +/- 35 to 203 +/- 25 mmHg (p < 0.001). All variations were still significant at 6 months.
  
  
  CONCLUSIONS
  These results suggest that captopril has a favourable effect on left ventricular mass, dimensions and load conditions, and could favourably influence the natural history of chronic aortic regurgitation. The efficacy of medical treatment can be verified through serial echocardiographic study.
authors.affiliation: Divisione di Cardiologia, Ospedale Civile dell'Annunziata, Cosenza.
authors.forename: G
authors.initials: G
authors.lastname: Bisignani
authors.forename: O
authors.initials: O
authors.lastname: Serafini
authors.forename: R
authors.initials: R
authors.lastname: Caporale
authors.forename: D
authors.initials: D
authors.lastname: Guzzo
authors.forename: F
authors.initials: F
authors.lastname: Plastina
mesh_terms: D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001022:Aortic Valve Insufficiency / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure; D002216:Captopril / Q000008:administration & dosage*; D002908:Chronic Disease; D003627:Data Interpretation, Statistical; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013318:Stroke Volume; D013997:Time Factors; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril